| Literature DB >> 22978749 |
Arnulf Langhammer1, Steinar Krokstad, Pål Romundstad, Jon Heggland, Jostein Holmen.
Abstract
BACKGROUND: Population based studies are important for prevalence, incidence and association studies, but their external validity might be threatened by decreasing participation rates. The 50 807 participants in the third survey of the HUNT Study (HUNT3, 2006-08), represented 54% of the invited, necessitating a nonparticipation study.Entities:
Mesh:
Year: 2012 PMID: 22978749 PMCID: PMC3512497 DOI: 10.1186/1471-2288-12-143
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.615
Comparisons of anthropometrics (means) and percentages reporting symptoms and diseases between responders to the main questionnaires (Q1 or Q2) and the nonparticipation questionnaire (QNP)
| | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number invited ¤ | 47 293 | 19 004 | | | 46 567 | 23020 | | | |
| Number participated | 27 758 | 3241 | | 30 999 | 23 049 | 3677 | | 26 726 | |
| Percent of invited to HUNT3 | 58.7 | 6.9 | | 65.6 | 49.5 | 7.9 | | 57.4 | |
| Height (cm) # | 164.6 | 166.3 | <0.01 | 164.7 | 177.8 | 179.6 | <0.01 | 178.0 | |
| Weight (kg) # | 72.9 | 71.5 | <0.01 | 72.8 | 86.9 | 86.7 | 0.51 | 86.8 | |
| BMI (kg/m2) # | 26.9 | 25.8 | <0.01 | 26.8 | 27.5 | 26.9 | <0.01 | 27.4 | |
| General practitioner last 12 months | 83.9 | 84.6 | 0.30 | 83.9 | 74.5 | 74.2 | 0.74 | 74.4 | |
| Hospitalized last year | 12.4 | 20.1 | <0.01 | 13.1 | 10.9 | 14.0 | <0.01 | 11.3 | |
| Current health poor or very poor | 28.4 | 29.6 | 0.20 | 28.5 | 23.4 | 24.1 | 0.36 | 23.5 | |
| Mental distress £ | 7.9 | 12.1 | <0.01 | 8.3 | 6.3 | 9.4 | <0.01 | 6.8 | |
| Insomnia many evenings a week | 14.8 | 16.2 | 0.03 | 15.0 | 7.5 | 10.2 | <0.01 | 8.0 | |
| Wake up early in the morning many days a week | 12.2 | 11.9 | 0.66 | 12.1 | 9.6 | 8.2 | <0.01 | 9.4 | |
| Chronic disease limiting daily functions | 33.9 | 33.9 | 1.00 | 33.9 | 32.4 | 27.9 | <0.01 | 31.8 | |
| Daily cough in periods (Q2) | 19.1 | 20.7 | 0.04 | 19.3 | 22.6 | 20.3 | <0.01 | 22.2 | |
| Attacks of wheezing or breathlessness | 12.4 | 11.3 | 0.09 | 12.3 | 12.3 | 12.2 | 0.95 | 12.3 | |
| Allergic rhinitis (Q2) | 23.1 | 25.3 | <0.01 | 23.4 | 18.7 | 21.8 | <0.01 | 19.2 | |
| Heartburn (a lot) (Q2) | 7.1 | 4.4 | <0.01 | 6.7 | 7.2 | 4.8 | <0.01 | 6.8 | |
| Headache (Q2) | 42.1 | 44.7 | <0.01 | 42.4 | 27.8 | 27.3 | 0.51 | 27.7 | |
| Migraine (Q2) | 10.9 | 11.8 | 0.09 | 11.0 | 5.0 | 5.3 | 0.45 | 5.0 | |
| Musculoskeletal pain of more than 3 months | 54.6 | 41.9 | <0.01 | 53.0 | 45.1 | 31.6 | <0.01 | 42.9 | |
| Urine incontinence (Q2) | 26.8 | 20.6 | <0.01 | 26.1 | 8.7 | 5.2 | <0.01 | 8.2 | |
| Medication for arterial hypertension | 20.5 | 24.9 | <0.01 | 20.8 | 21.4 | 23.8 | <0.01 | 21.7 | |
| Myocardial infarction | 1.6 | 3.1 | <0.01 | 1.7 | 5.2 | 6.9 | <0.01 | 5.4 | |
| Angina pectoris | 2.5 | 3.2 | 0.04 | 2.7 | 4.8 | 5.9 | 0.01 | 5.0 | |
| Cerebral insult | 2.2 | 3.5 | <0.01 | 2.3 | 3.0 | 3.7 | 0.03 | 3.1 | |
| Renal disease | 2.6 | 3.9 | <0.01 | 2.7 | 2.5 | 3.8 | <0.01 | 2.7 | |
| Asthma | 10.4 | 10.9 | 0.39 | 10.4 | 9.4 | 10.5 | 0.04 | 9.5 | |
| COPD or chronic bronchitis | 3.3 | 3.9 | 0.14 | 3.3 | 3.4 | 5.3 | <0.01 | 3.7 | |
| Diabetes | 3.8 | 5.7 | <0.01 | 4.0 | 4.9 | 6.6 | <0.01 | 5.2 | |
| Cancer | 5.6 | 5.6 | 0.94 | 5.6 | 4.9 | 4.6 | 0.55 | 4.8 | |
| Osteoporosis | 5.3 | 5.9 | 0.20 | 5.3 | 0.7 | 1.1 | 0.03 | 0.8 | |
| Fibromyalgia | 6.3 | 7.4 | 0.03 | 6.4 | 0.8 | 1.3 | <0.01 | 0.9 | |
| Arthrosis | 18.8 | 21.4 | <0.01 | 19.0 | 10.3 | 11.9 | 0.01 | 10.5 | |
| Sought help for mental problem | 16.9 | 20.6 | <0.01 | 17.7 | 9.9 | 11.7 | <0.01 | 10.1 | |
| Hyperthyreosis | 2.8 | 3.0 | 0.56 | 2.8 | 0.9 | 0.5 | 0.05 | 0.8 | |
| Hypothyreosis | 9.3 | 10.0 | 0.30 | 9.4 | 2.3 | 1.8 | 0.06 | 2.2 | |
| Never-smoker § | 47.3 | 44.4 | <0.01 | 47.0 | 44.3 | 41.1 | <0.01 | 43.8 | |
| Ex-smoker | 27.4 | 26.1 | 0.13 | 27.3 | 35.2 | 31.1 | <0.01 | 34.6 | |
| Occasional smoker | 9.4 | 9.3 | 0.92 | 9.4 | 9.7 | 9.2 | 0.38 | 9.6 | |
| Daily smoker | 20.6 | 20.2 | 0.59 | 20.6 | 16.9 | 18.7 | <0.01 | 17.1 | |
| Daily use of snuff | 1.2 | 1.9 | <0.01 | 1.3 | 13.8 | 17.0 | <0.01 | 14.3 | |
| Alcohol | 12.0 | 9.5 | <0.01 | 11.3 | 18.8 | 17.8 | 0.16 | 18.6 | |
| Exercise | 20.5 | 14.0 | <0.01 | 19.8 | 17.3 | 13.9 | <0.01 | 16.9 | |
Questions from Q2 are marked.
¤ Invited to QNP, persons having died or emigrated between HUNT3 and QNP are excluded.
# Height and weight measured at the screening stations, self-reported in QNP.
§ Questions on tobacco smoking; included in n if answered at least one of the smoking related questions.
£ CONOR Mental Health Index (CONOR MHI) consists of 7 questions on mental distress with score 1-4. Mean score calculated and cut-off for dichotomization was ≥ 2.15.
Corresponding data stratified by age and sex are given in Table S1 and Table S2.
Number of persons, mean age and percentages having consulted general practitioner in the last 12 months among those having answered HUNT3 questionnaire Q1 and those being registered at the general practices
| Numbers | | |||||||
| HUNT3: Invited | 8606 | 10 577 | 6274 | 1400 | 8528 | 10 093 | 6537 | 2299 |
| HUNT3: Answered Q1 | 2785 | 5657 | 4057 | 552 | 3898 | 6510 | 4631 | 782 |
| GPs: Listed patients aged ≥ 20 years | 4364 | 5346 | 3926 | 818 | 3848 | 5209 | 3559 | 1205 |
| Mean age | | |||||||
| HUNT3: Mean age within age groups among all invited | 29.7 | 49.4 | 67.7 | 84.4 | 29.7 | 49.4 | 68.1 | 85.3 |
| HUNT3: Mean age within age groups among all Q1 part. | 31.4 | 50.5 | 68.0 | 83.8 | 31.2 | 50.3 | 68.2 | 84.2 |
| GPs: Mean age within age groups in the patient population | 29.0 | 49.4 | 67.6 | 84.8 | 29.4 | 49.2 | 68.0 | 85.7 |
| Consultations | | |||||||
| HUNT3 Reported GP visit last year | 65.0 | 71.7 | 86.3 | 93.7 | 82.7 | 82.3 | 89.7 | 92.3 |
| GP: Registered | 58.9 | 71.3 | 86.5 | 92.7 | 78.9 | 84.5 | 90.2 | 89.2 |
Data restricted to the municipalities including eight randomly selected general practices (GPs). The 28 872 HUNT3 participants represented 57% of invited in these municipalities.
Prevalence data (%) based on HUNT3 questionnaires (Q1 or Q2) and general practitioner diagnoses (GPD)
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| Q2: A lot of heart burn | 6.1 | 7.9 | 6.3 | 6.2 | 4.9 | 6.3 | 8.6 | 7.9 |
| GPD: Heart burn or reflux (D03/D84) | 3.9 | 8.2 | 10.0 | 11.0 | 2.5 | 7.6 | 12.1 | 12.0 |
| Q1: Angina pectoris | 0.3 | 1.5 | 9.6 | 21.4 | 0.2 | 0.7 | 4.4 | 15.5 |
| GPD: Angina pectoris (K74) | 0.1 | 2.2 | 13.9 | 26.4 | 0 | 0.8 | 6.8 | 21.1 |
| Q1: Myocardial infarction | 0.1 | 2.3 | 10.1 | 21.2 | 0.0 | 0.5 | 3.0 | 8.6 |
| GPD: Myocardial infarction (K75or K76) | 1.0 | 3.3 | 12.9 | 18.8 | 0.5 | 1.3 | 4.7 | 10.4 |
| Q1: Cerebral insult | 0.6 | 1.5 | 5.4 | 11.6 | 0.3 | 1.1 | 3.9 | 8.6 |
| GPD: Cerebral insult (K90 + 91) | 0.4 | 2.2 | 7.3 | 17.0 | 0.4 | 1.4 | 5.7 | 14.2 |
| Q1: Arterial hypertension | 1.2 | 14.7 | 38.1 | 44.1 | 2.1 | 12.7 | 36.9 | 49.8 |
| GPD: Arterial hypertension (K86 or K87) | 2.7 | 14.7 | 37.4 | 42.2 | 2.2 | 12.9 | 37.1 | 49.4 |
| NorPD: Drugs arterial hyper-tension (C02-03, 07–09) | 1.7 | 16.0 | 51.5 | 70.3 | 2.2 | 15.7 | 49.5 | 67.7 |
| Q1: Spondylarthritis or | ||||||||
| rheumatoid arthritis | 1.5 | 4.1 | 5.3 | 6.0 | 1.9 | 4.7 | 7.2 | 8.8 |
| GPD: Spondylarthritis or rheumatoid arthritis (L88) | 1.5 | 3.4 | 4.5 | 5.6 | 1.5 | 4.7 | 7.9 | 8.7 |
| Q1: Arthrosis | 0.8 | 6.1 | 17.2 | 23.3 | 1.0 | 12.8 | 34.2 | 45.5 |
| GPD: Arthrosis hip or knee (L 89 + 90 + 91) | 1.7 | 7.5 | 21.5 | 29.8 | 1.7 | 10.2 | 33.6 | 43.4 |
| Q1: Osteoporosis | 0.1 | 0.3 | 1.2 | 3.1 | 0.3 | 1.9 | 11.1 | 20.6 |
| GPD: Osteoporosis L95 | 0.2 | 0.6 | 1.5 | 2.9 | 0.2 | 1.4 | 10.8 | 22.7 |
| Q1: Headache | 37.0 | 34.3 | 18.7 | 10.7 | 56.9 | 47.7 | 26.8 | 16.6 |
| GPD: Headache (N01) | 10.8 | 9.9 | 7.9 | 6.1 | 18.6 | 16.5 | 12.6 | 11.0 |
| Q1: Migraine | 3.1 | 4.5 | 2.7 | 3.4 | 10.4 | 11.2 | 5.1 | 5.0 |
| GPD: Migraine (N89) | 3.8 | 4.4 | 2.6 | 1.5 | 9.5 | 11.6 | 7.1 | 2.4 |
| NorPD: Use of migraine drugs (N02) | 1.0 | 1.0 | 0.5 | 0.2 | 3.5 | 4.9 | 2.0 | 0.3 |
| Q1: Epilepsy | 1.5 | 1.2 | 1.2 | 1.9 | 1.3 | 1.4 | 0.7 | 1.4 |
| GPD: Epilepsy (N88) | 1.8 | 1.7 | 1.8 | 1.5 | 1.5 | 1.7 | 1.5 | 1.2 |
| Q2: HADS anxiety score | 11.9 | 11.7 | 7.2 | 8.2 | 18.4 | 17.4 | 15.6 | 13.2 |
| GPD: Anxiety or feeling of anxiety (P 01 + 74 +79) | 6.7 | 8.5 | 8.5 | 8.6 | 9.7 | 14.1 | 14.0 | 15.4 |
| Q2: HADS depression score | 6.4 | 9.4 | 11.7 | 18.8 | 6.2 | 8.3 | 9.8 | 16.3 |
| GPD: Depression or feeling of depression (P 03 + 76) | 11.0 | 18.1 | 16.0 | 11.1 | 19.6 | 31.3 | 28.0 | 21.7 |
| Q2: Insomnia many evenings or mornings a week | 11.6 | 13.8 | 16.2 | 15.4 | 13.1 | 21.3 | 25.8 | 25.3 |
| GPD: Sleeping disorder (P06) | 6.3 | 8.6 | 18.8 | 24.0 | 6.3 | 13.3 | 21.7 | 32.4 |
| Q1: COPD or chronic bronch | 1.0 | 2.0 | 5.6 | 5.4 | 1.5 | 2.7 | 4.6 | 4.2 |
| GPD: COPD or chronic bronchitis (R95) | 0.1 | 1.9 | 7.9 | 13.2 | 0.2 | 1.8 | 7.2 | 7.0 |
| Q1: Asthma | 10.5 | 9.3 | 9.4 | 7.2 | 12.4 | 9.4 | 10.4 | 8.6 |
| GPD: Asthma (R96) | 10.6 | 7.0 | 9.2 | 10.0 | 10.4 | 9.7 | 11.9 | 9.9 |
| Q1: Use of asthma or copd drugs in the last 5 years | 8.1 | 7.5 | 11.3 | 9.6 | 10.4 | 9.6 | 12.5 | 9.7 |
| GP prescription asthma drugs in the last 5 year (R03) | 7.4 | 8.7 | 15.1 | 17.4 | 9.8 | 11.4 | 17.3 | 12.6 |
| NorPD: Use of asthma drugs in 2008 (R03) | 4.6 | 5.6 | 11.6 | 14.2 | 5.7 | 7.7 | 13.0 | 9.1 |
| Q1: Psoriasis | 4.1 | 6.8 | 7.0 | 3.8 | 3.3 | 6.2 | 6.6 | 4.1 |
| GPD: Psoriasis (S91) | 2.0 | 4.6 | 5.5 | 4.6 | 2.7 | 4.5 | 5.8 | 2.8 |
| Q1: Hyperthyreosis | 0.3 | 0.7 | 1.3 | 2.5 | 1.4 | 2.6 | 3.4 | 3.2 |
| GPD: Hyperthyreosis (T85) | 0.2 | 0.5 | 0.7 | 0.7 | 0.6 | 1.9 | 2.0 | 2.0 |
| Q1: Hypothyreosis | 0.6 | 2.1 | 2.9 | 5.3 | 4.1 | 8.0 | 12.3 | 12.1 |
| GPD: Hypothyreosis (T86) | 1.4 | 1.9 | 4.2 | 6.7 | 3.2 | 7.8 | 12.7 | 13.8 |
| GP prescription thyroid hormone (H03AA01) | 0.5 | 1.5 | 3.3 | 5.1 | 2.2 | 7.0 | 12.1 | 12.5 |
| NorPD: Use of thyroid hormone (H03AA01) | 0.5 | 2.0 | 3.7 | 5.9 | 2.6 | 7.9 | 14.2 | 13.4 |
| Q1: Diabetes mellitus | 0.8 | 3.4 | 9.2 | 9.2 | 0.8 | 2.4 | 6.9 | 9.7 |
| GPD: Diabetes mellitus (T89 + 90) | 1.2 | 4.8 | 13.7 | 16.3 | 1.4 | 3.6 | 10.4 | 13.0 |
| GP prescription antidiabetic drug (A10A or A10B) | 0.8 | 4.0 | 10.9 | 10.9 | 1.2 | 2.8 | 7.9 | 8.8 |
| NorPD: Antidiabetic drug (A10A or A10B) | 1.1 | 4.1 | 11.1 | 11.7 | 1.5 | 2.6 | 8.4 | 9.2 |
| Q2: Urinary incontinence | 4.7 | 7.6 | 10.4 | 13.1 | 22.2 | 27.5 | 27.4 | 32.8 |
| GPD: Urinary incontinence (U04) | 1.0 | 0.5 | 3.0 | 8.7 | 2.2 | 6.8 | 10.5 | 22.0 |
HUNT data are restricted to the municipalities being represented by eight randomly selected general practices, and include 28 872 HUNT3 participants (57% of invited in these municipalities). Data from Norwegian Prescription Registry (NorPD) include the entire county for the year 2008.
# Hospital Anxiety and Depression Scale (HADS) 14 items, cut-off 8 indicate minor, moderate and severe disease (REF).
In parenthesis: For diagnosis – codes according to the International Classification of Primary Care (ICPC2), for medication codes according to The Anatomical Therapeutic Chemical Classification System (ATC).
Figure 1Prevalence of diseases (%) based on GP records, HUNT questionnaire 1 (Q1) and QNP by age group.
Percentages reporting reasons for nonparticipation in the HUNT study among 3241 women (W) and 3677 men (M) having answered the nonparticipation questionnaire (QNP)
| Did not receive the invitation | 13.3 | 14.9 | 6.2 | 9.3 | 8.5 | 9.1 | 8.0 | 10.7 | 9.5 | 11.1 | 0.02 |
| Had not time /inconvenient session | 60.7 | 64.5 | 54.9 | 61.9 | 34.8 | 40.2 | 14.3 | 20.8 | 50.7 | 56.6 | <0.01 |
| Don’t rely on such examinations | 0.2 | 0.9 | 1.1 | 1.6 | 1.7 | 2.2 | 0.4 | 2.0 | 0.8 | 1.5 | <0.01 |
| No benefit of such examinations | 0.3 | 1.7 | 1.6 | 1.8 | 3.1 | 4.8 | 6.3 | 8.1 | 1.7 | 2.6 | <0.01 |
| Too ill to attend the study | 1.4 | 0.6 | 3.3 | 1.2 | 7.2 | 5.5 | 23.7 | 19.5 | 4.7 | 2.6 | <0.01 |
| Questions I did not wish to answer | 2.1 | 1.2 | 3.9 | 3.5 | 6.8 | 7.0 | 3.6 | 4.0 | 3.7 | 3.5 | 0.61 |
| Other reason | 25.1 | 17.5 | 30.0 | 22.1 | 32.1 | 27.2 | 24.6 | 18.8 | 28.1 | 21.5 | <0.01 |
§ p-values for chi-square tests comparing all men and women.
Prevalence ratio and absolute difference (%) of participation (n = 50 807)no participation*(n = 36 135) in the HUNT3 main questionnaire by different characteristics
| Sex (women/men) | 1.17 | 1.23 | 1.20, 1.26 | 9.2 | 12.6 | 11.8,13.3 |
| 20-39 year | 1 | 1 | Reference | 0 | 0 | Reference |
| 40-59 year | 1.63 | 1.45 | 1.40, 1.50 | 25.2 | 19.1 | 18.2, 20.0 |
| 60-79 year | 1.88 | 1.74 | 1.68, 1.81 | 34.7 | 29.9 | 29.0, 30.8 |
| 80 + yrs | 1.12 | 1.23 | 1.16, 1.30 | 4.8 | 10.7 | 9.2, 12.1 |
| 9 year or less | 1 | 1 | Reference | 0 | 0 | Reference |
| 10-12 year | 1.28 | 1.27 | 1.23, 1.30 | 13.6 | 13.6 | 12.8, 14.5 |
| University | 1.39 | 1.36 | 1.31, 1.41 | 19.0 | 17.4 | 16.4, 18.4 |
| Unmarried | 1 | 1 | Reference | 0 | 0 | Reference |
| Divorced/Widower | 1.27 | 1.01 | 0.97, 1.05 | 11.6 | −1.8 | −3.0, -0.6 |
| Married/cohabits | 1.64 | 1.29 | 1.25, 1.33 | 27.3 | 14.5 | 13.5, 15.4 |
| Quintile 1 | 1 | 1 | Reference | 0 | 0 | Reference |
| Quintile 3 | 1.39 | 1.32 | 1.09, 1.60 | 15.9 | 15.1 | 10.0, 20.1 |
| Quintile 5 | 1.49 | 1.42 | 1.17, 1.73 | 20.4 | 20.4 | 15.6, 25.1 |
| Urban / rural | 0.93 | 0.91 | 0.89, 0.93 | 6.1 | −5.6 | −6.4, -4.7 |
| Disability pension | 0.97 | 0.92 | 0.88, 0.96 | −19.2 | −6.5 | −7.8, -5.2 |
| Social benefit | 0.43 | 0.61 | 0.56, 0.67 | −32.8 | −17.9 | −20.2,-15.5 |
*Participants that answered the nonparticipation questionnaire (QNP) were not included.
¤ Binomial regression, adjusted for all other variables except social security factors.
#Analysis restricted to subjects below 65 years of age and all variables entered in the adjusted model.
Overall and sex specific age adjusted mortality (hazard ratio with 95% CI) according to participation in the HUNT 1, HUNT 2 and the HUNT 3 study
| Women | ||||
| Participated | 38698 | 13450 | 1.00 | Reference |
| Not participated | 3571 | 1300 | 1.51 | 1.43-1.60 |
| Men | ||||
| Participated | 36928 | 14206 | 1.00 | Reference |
| Not participated | 5018 | 1391 | 1.55 | 1.46-1.64 |
| Overall | ||||
| Participated | 75626 | 27656 | 1.00 | Reference |
| Not participated | 8589 | 2691 | 1.50 | 1.44-1.57 |
| Women | ||||
| Participated | 34469 | 5087 | 1.00 | Reference |
| Not participated | 9700 | 2833 | 1.82 | 1.74-1.91 |
| Men | ||||
| Participated | 30237 | 5497 | 1.00 | Reference |
| Not participated | 12625 | 2261 | 1.64 | 1.56-1.73 |
| Overall | ||||
| Participated | 64706 | 10584 | 1.00 | Reference |
| Not participated | 22325 | 5094 | 1.72 | 1.66-1.78 |
| Women | ||||
| Participated | 27652 | 835 | 1.00 | Reference |
| Not participated | 19405 | 225 | 3.33 | 2.86-3.87 |
| Men | ||||
| Participated | 22918 | 367 | 1.00 | Reference |
| Not participated | 23443 | 702 | 2.41 | 2.12-1.75 |
| Overall | ||||
| Participated | 50571 | 619 | 1.00 | Reference |
| Not participated | 42848 | 1555 | 2.80 | 2.54-3.09 |
Adjusted for age by using age as the time scale.
The following subjects are excluded from the analyses: Persons < 20 years of age at baseline study, and deaths between invitation and August 1986, August 1997, and August 2008 for HUNT1, HUNT2 and HUNT3, respectively. The number of participants and nonparticipants therefore are lower than previously for the entire study population.
Figure 2Overall survival by participation in HUNT 1 in men and women. Age used as timescale.
Figure 3Overall survival by participation in HUINT 2 in men and women. Age used as timescale.
Figure 4Overall survival by participation in HUNT 3 in men and women. Age used as timescale.
Figure 5Risk of death by participation in HUNT 1 in men and women adjusted for age (estimated at 50 years of age at participation).
Figure 6Risk of death by participation in HUNT 2 in men and women adjusted for age (estimated at 50 years of age at participation).
Figure 7Risk of death by participation in HUNT 3 in men and women adjusted for age (estimated at 50 years of age at participation).